---
figid: PMC9525711__41401_2022_888_Fig3_HTML
pmcid: PMC9525711
image_filename: 41401_2022_888_Fig3_HTML.jpg
figure_link: /pmc/articles/PMC9525711/figure/Fig3/
number: Fig. 3
figure_title: Effects of TLB on redox status in the APP/PS1 mice
caption: 'a ROS level. b MDA level (n = 5). c 4-HNE level (n = 5). d 8-isoprostane
  level (n = 5). e SOD activity (n = 5). f SOD1 activity (n = 5). g SOD2 activity
  (n = 5). h SOD3 activity (n = 5). i GSH-Px activity (n = 5). j CAT activity (n = 5).
  k DHE signal (red) indicated the levels of superoxide in the hippocampus of APP/PS1
  mice or age-matched WT mice. l DHE intensity in CA1 region of hippocampus (n = 5).
  m DHE intensity in CA3 region of hippocampus (n = 5). n DHE intensity in DG region
  of hippocampus (n = 5). o Representative Western blots of SIRT3, ac-SOD2 and SOD2.
  p Quantitation of SIRT3 protein expression. q Quantitation of ac-SOD2 level (n = 5).
  The data were presented as the mean ± SEM. **P < 0.01 vs. WT group; #P < 0.05, ##P < 0.01
  vs. APP/PS1 group.'
article_title: Trilobatin rescues cognitive impairment of Alzheimer’s disease by targeting
  HMGB1 through mediating SIRT3/SOD2 signaling pathway.
citation: Jian-mei Gao, et al. Acta Pharmacol Sin. 2022 Oct;43(10):2482-2494.
year: '2022'

doi: 10.1038/s41401-022-00888-5
journal_title: Acta Pharmacologica Sinica
journal_nlm_ta: Acta Pharmacol Sin
publisher_name: Springer Nature Singapore

keywords:
- trilobatin
- Alzheimer’s disease
- Aβ25-35
- HMGB1
- neuroinflammation
- oxidative stress

---
